Tiotropium Plus Olodaterol Fixed-Dose Combination Therapy Provides Lung Function Benefits When Compared With Tiotropium Alone, Irrespective Of Prior Treatment With A Long-Acting B…

Rationale: Tiotropium + olodaterol (T+O) is a novel once-daily, fixed-dose combination of the long-acting muscarinic antagonist (LAMA) tiotropium (T) and the long-acting β2-agonist (LABA) olodaterol, for use as maintenance treatment in chronic obstructive pulmonary disease (COPD). These post hoc analyses of data from the two pivotal 1-year TONADO studies determined whether treatment with a long-acting bronchodilator (LABD) prior to randomization affected the lung-function benefits of T+O 5/5 µg (via Respimat®) compared to T 5 µg (Respimat®). Methods: 2124 patients had not received prior LABD treatment (T+O n = 4…